决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:E3 ubiquitin ligase NKLAM/RNF19b suppresses myc-driven B cell lymphomagenesis in Eμ-myc mice.
这些研究表明,NKLAM在myc驱动的B细胞淋巴瘤发生的早期和晚期阶段均发挥作用:首先通过限制非恶性前B细胞中myc和Bcl-2的表达,从而延长无肿瘤生存期。随后,NKLAM+免疫细胞进行免疫编辑,导致IgM-淋巴瘤的发生,这类淋巴瘤免疫原性较低且侵袭性更强。
NK 细胞裂解相关分子(NKLAM)(也称为 RNF19b)是一种膜结合 E3 泛素连接酶。既往研究表明,NKLAM 在自然杀伤(NK)细胞功能以及巨噬细胞产生促炎细胞因子中发挥作用。使用淋巴瘤、黑色素瘤和乳腺癌细胞的研究发现,NKLAM 缺陷敲除(KO)小鼠的肿瘤播散和转移多于野生型(WT)小鼠,表明 NKLAM 参与体内控制肿瘤发展。
我们采用Eμ-myc小鼠模型来确定NKLAM是否影响B细胞淋巴瘤的发生。在年轻的Eμ-myc小鼠中,B系细胞中myc的过表达导致非肿瘤性前体B细胞扩增,随后这些细胞消失。随着时间推移,会发展为pre-B、pro-B或未成熟B细胞淋巴瘤。
NKLAM KO Eμ-myc小鼠的前体B细胞水平高于WT转基因小鼠。这些细胞表达更多的myc和Bcl-2,并持续更长时间。NKLAM KO Eμ-myc小鼠的淋巴瘤发展更快,并且显著具有更分化的表型,以表面IgM为特征。当注射到非转基因小鼠体内时,这些淋巴瘤也比IgM-肿瘤侵袭性更低。将NKLAM+免疫细胞输注到年轻的NKLAM KO Eμ-myc小鼠中可延长其生存期,这增加了发展为更具侵袭性、免疫耐受的IgM-淋巴瘤的小鼠比例。
INTRODUCTION: Natural Killer Lytic-Associated Molecule (NKLAM) (also known as RNF19b) is a membrane-bound E3 ubiquitin ligase. Previous studies demonstrated a role of NKLAM in natural killer (NK) cell function and pro-inflammatory cytokine production by macrophages. Studies using lymphoma, melanoma and breast cancer cells found that tumor dissemination and metastasis are greater in NKLAM-deficient knockout (KO) mice than in wild type (WT) mice, indicating that NKLAM participates in controlling tumor development in vivo . METHODS: We employed the Eμ-myc mouse model to determine whether NKLAM influences B cell lymphomagenesis. In young Eμ-myc mice, overexpression of myc in B lineage cells leads to expansion of non-neoplastic precursor B cells, which subsequently disappear. Over time, pre-B, pro-B or immature B cell lymphomas develop. RESULTS: NKLAM KO Eμ-myc mice have higher levels of precursor B cells than WT transgenic mice. These cells express more myc and Bcl-2 and persist longer. Lymphomas develop more rapidly in NKLAM KO Eμ-myc mice and strikingly, have a more differentiated phenotype, characterized by surface IgM. These lymphomas are also less aggressive than IgM- tumors when injected into non-transgenic mice. Infusion of NKLAM+ immune cells into young NKLAM KO Eμ-myc mice extends their survival, which increases the proportion of mice that develop more aggressive, immune-resistant IgM- lymphomas. DISCUSSION: These studies indicate that NKLAM contributes to both the early and late phases of myc-driven B cell lymphomagenesis, first by limiting expression of myc and Bcl-2 within the non-malignant pre-B cells, resulting in longer tumor-free survival. This is followed by immunoediting by NKLAM+ immune cells, leading to development of IgM- lymphomas that are less immunogenic and more aggressive.
MEMBER ACCOUNT
登录成功会直接打开下一页。